Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANT-501
- Development stage
- Preclinical
- Lead developer
- Anterogen
- Modality
- Small Molecules
01
Overview
ANT-501 is a preclinical-stage nucleoside analog antiviral candidate being developed by Anterogen. It is specifically targeted toward the treatment of Herpes Simplex Virus (HSV) and Herpes Zoster (shingles), caused by the Varicella-Zoster Virus (VZV). As a nucleoside analog, ANT-501 is expected to function by interfering with viral DNA synthesis, typically through the inhibition of viral DNA polymerase or by acting as a chain terminator during DNA replication. This mechanism effectively halts the proliferation of the virus within the host. The drug is currently undergoing preclinical evaluation to assess its efficacy and safety profile for these viral indications.
02
Targets
DNA polymerase family
Beyond the preview
Go deeper on ANT-501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANT-501.